ArticleLeukemia2026
SLF2 and SMC5 dysfunction drives HSC aging and predisposes to MDS, defining a new inherited bone marrow failure syndrome.
Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Inherited bone marrow failure syndromes (IBMFS) comprise a heterogeneous group of genetic disorders and are associated with an increased risk of myelodysplastic syndromes (MDS). We and others recently identified pathogenic variants in SLF2 and SMC5 as the cause of Atelis Syndrome, a neurodevelopmental disorder accompanied by hematological abnormalities, including anemia and lymphopenia. However, the mechanisms underlying the associated hematopoietic dysfunction remain unclear. Through longitudinal follow-up and re-evaluation, we found that some patients developed MDS at a young age. To elucidate the bases of these hematopoietic defects, we analyzed hematopoietic progenitor cells (HPCs) derived from patient-specific induced pluripotent stem cells harboring compound heterozygous SLF2 mutations. Mutant HPCs exhibited impaired colony-forming capacity, defective erythroid differentiation with a myeloid bias, and markedly reduced engraftment in xenotransplantation assays. SMC5 knockdown in cord blood CD34
Identifiers
42562919What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.